Case series of retinopathy of prematurity blindness in Nigeria: A wakeup call to policy makers, hospitals, ophthalmologists and paediatricians

2021 ◽  
Vol 28 (4) ◽  
pp. 303
Author(s):  
DupeSerifat Ademola-Popoola ◽  
AdeolaO Onakoya ◽  
ChinyeluNkemdilim Ezisi ◽  
ValentinaWinifred Okeigbemen ◽  
AdaE Aghaji ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Policy Makers

Case series of angle-closure glaucoma after laser treatment for retinopathy of prematurity

2005 ◽  
Vol 9 (1) ◽  
pp. 17-21 ◽  
Author(s):  
Lucas Trigler ◽  
R. Grey Weaver ◽  
James W. O’Neil ◽  
Michael J. Barondes ◽  
Sharon F. Freedman
Keyword(s):  
Laser Treatment ◽  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Angle Closure Glaucoma ◽  
Angle Closure

Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series

2018 ◽  
Vol 30 (1) ◽  
pp. 40-47 ◽  
Author(s):  
Islam SH Ahmed ◽  
Ahmed MA Hadi ◽  
Hassan H Hassan
Keyword(s):  
Side Effects ◽  
Intravitreal Injection ◽  
Retinopathy Of Prematurity ◽  
Large Scale ◽  
Low Dose ◽  
Case Series ◽  
Results Of Treatment ◽  
Case Series Study ◽  
Systemic Side Effects

Aim: To report the results of treatment of type 1 prethreshold retinopathy of prematurity using intravitreal injection of ultra-low dose of ranibizumab (0.1 mg in 0.01 mL). Design: A retrospective observational case series study. Methods: Review of files of eligible infants who received this form of treatment to determine the outcome of treatment and any associated ocular or systemic side effects. Results: The study included 24 eyes of 12 preterm infants with mean gestational age of 29.75 ± 1.54 weeks and mean birth weight of 1074.58 ± 320.59 g. A total of 22 eyes (91.67%) had zone II disease while 2 eyes of one infant (8.33%) had zone I disease. All cases showed regression of the signs of the active retinopathy of prematurity with complete retinal vascularization. None of the cases required retreatment. Three eyes developed ocular complications. Apart from mild feeding intolerance that lasted for 24 h after injection in one infant, none of the cases developed systemic side effects. Conclusion: Intravitreal injection of ultra-low-dose ranibizumab showed promising efficacy and good ocular safety. However, further large-scale studies are required to give stronger evidence about the efficacy and safety of ultra-low-dose ranibizumab.

scholarly journals Neurodevelopment in patients with retinopathy of prematurity treated with intravitreal bevacizumab. Case series

2017 ◽  
Vol 85 (6) ◽  
pp. 478-484
Author(s):  
Sarah Melania Martínez-García ◽  
Sergio Eustolio Hernández-Da Mota ◽  
Araceli Rubio-Rangel ◽  
Ignacio Rojas-Flores ◽  
Mayra Edith Vieyra-López ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Intravitreal Bevacizumab

scholarly journals Systemic adverse events after screening of retinopathy of prematurity with mydriatic

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0256878
Author(s):  
Shumpei Obata ◽  
Taku Imamura ◽  
Masashi Kakinoki ◽  
Takahide Yanagi ◽  
Yoshihiro Maruo ◽  
...  
Keyword(s):  
Body Weight ◽  
Adverse Events ◽  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Abdominal Distension ◽  
Abdominal Distention ◽  
Retrospective Case ◽  
Lower Body Weight ◽  
Case Series Study ◽  
Before And After

Purpose To evaluate systemic adverse events after screening for retinopathy of prematurity (ROP) performed with mydriatic. Methods This was a retrospective case series study. Medical records of consecutive patients who underwent screening for ROP with 0.5% phenylephrine and 0.5% tropicamide eyedrops were retrospectively reviewed. The score of abdominal distention (0–5), volume of milk sucked and volume of stool, along with systemic details (pulse and respiration rates, blood pressure and number of periods of apnea) were collected at 1 week and 1 day before ROP examination, and at 1 day after examination. Results were compared between the days before and after examination. Correlation between body weight at the time of examination and the score of abdominal distention was examined. The numbers of infants with abdominal and/or systemic adverse events were compared between pre- and post-examination periods. Results Eighty-six infants met the inclusion criteria. The score of abdominal distention increased from 2.0 at 1 day before examination to 2.3 at 1 day after examination (p = 0.005), and the number of infants who had worsened abdominal distension increased after examination (p = 0.01). Infants with lower body weight had a higher score of abdominal distention (p < 0.0001, r = −0.57). The number of infants with reduced milk consumption increased after examination (p = 0.0001), as did the number of infants with decreased pulse rate (p = 0.0008). Conclusions Screening for ROP with mydriatic may have adverse effects on systemic conditions. Infants should be carefully monitored after ROP screening with mydriatic.

scholarly journals Paradoxical myopic shift following cycloplegia in retinopathy of prematurity patients: a case series

Cases Journal ◽  
2009 ◽  
Vol 2 (1) ◽  
pp. 8970 ◽  
Author(s):  
Nikolas JS London ◽  
Susan M Carden ◽  
William V Good
Keyword(s):  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Myopic Shift

Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series

2011 ◽  
Vol 249 (9) ◽  
pp. 1295-1301 ◽  
Author(s):  
Ramak Roohipoor ◽  
Hamed Ghasemi ◽  
Fariba Ghassemi ◽  
Reza Karkhaneh ◽  
Mohammad Riazi-Esfahani ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Intravitreal Bevacizumab

Fluorescein Angiography of Persistent Incomplete Vascularization of the Retina After Bevacizumab Therapy in Retinopathy of Prematurity

2019 ◽  
Vol 3 (5) ◽  
pp. 304-308 ◽  
Author(s):  
Xihui Lin ◽  
Sagar B. Patel ◽  
Alice Y. Zhang ◽  
Daniel A. Brill ◽  
Kim H. Le ◽  
...  
Keyword(s):  
Fluorescein Angiography ◽  
Gestational Age ◽  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Intravitreal Bevacizumab ◽  
Peripheral Retina ◽  
Medical Systems ◽  
Retrospective Case ◽  
Type 1 Rop

Purpose: This study evaluates the vascular development of premature infants at 50 weeks postconception after treatment with intravitreal bevacizumab for type 1 retinopathy of prematurity (ROP). Methods: A retrospective case series was conducted on type 1 ROP neonates with a high risk of general anesthesia complications. Patients were treated with bevacizumab between February 2013 and February 2016. At 50 weeks’ gestational age, all patients were imaged with RetCam (Clarity Medical Systems, Inc) fundus photographs and widefield fluorescein angiography (FA). Results: There were 4 boys and 7 girls with an average gestational age of 24.8 weeks and weight of 734.3 grams at birth. The estimated gestational age at injection was 37.1 weeks. Examination under anesthesia with FA was performed at a mean of 61 weeks posttreatment. Nineteen of 20 eyes (95%) of 11 infants had incomplete vascularization and peripheral nonperfusion on imaging. FA showed new vessels with increased tortuosity, microvascular abnormalities, and leakage past the original ridge. These 19 patients were treated with confluent ablative photocoagulation to the peripheral nonperfused retina. Patients were followed for a mean of 73.3 weeks after birth. None required incisional surgery. Conclusions: Patients with type 1 ROP treated with bevacizumab may have delayed vascularization of the peripheral retina and even late recurrence of active disease. Clinicians should regularly monitor patients after bevacizumab for potential neovascular complications.

scholarly journals Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity

2019 ◽  
Vol 28 (6) ◽  
pp. 526-532 ◽  
Author(s):  
Tariq Aldebasi ◽  
Muataz A. Guma ◽  
Rabia Bashir ◽  
Saif Al Saif ◽  
Waleed A. Altwaijri ◽  
...  
Keyword(s):  
Retinopathy Of Prematurity ◽  
Single Injection ◽  
Case Series ◽  
Severe Hypoglycemia ◽  
Stage Iii ◽  
Complete Regression ◽  
Intravitreal Ranibizumab ◽  
Retrospective Case ◽  
Case Series Study ◽  
Medical City

Objectives: To evaluate the efficacy of a single injection of 0.3 mg intravitreal ranibizumab for the treatment of retinopathy of prematurity (ROP). Methods:We conducted this retrospective case series study at King Abdul Aziz Medical City, Riyadh, Saudi Arabia. Seventy-four eyes of 37 preterm infants with ROP stage III with plus disease in zone I, posterior zone II, and aggressive posterior ROP received a single injection of 0.3 mg intravitreal ranibizumab. The favorable outcome measure was complete regression of the disease with normal vascularization of the retina of those infants. Results: The gestational age of the 37 included cases was in the range of 23–28 weeks and their body weight at birth was between 510 and 1,235 g except for one case with 2,550 g under oxygen therapy <7days with severe hypoglycemia. All eyes showed a favorable response in terms of regression of plus disease from the first day after treatment, followed by regression of stage III retinopathy. All patients developed complete vascularization over variable periods of time. Conclusion: One injection of 0.3 mg intravitreal ranibizumab is effective in treating ROP stage III mainly in zones I and II.

scholarly journals Serum levels of cytokines in infants treated with Conbercept for retinopathy of prematurity

2019 ◽  
Author(s):  
Yong Cheng ◽  
Xuemei Zhu ◽  
Dandan Linghu ◽  
Zhongxu Jia ◽  
Yongsheng Xu ◽  
...  
Keyword(s):  
Growth Factor ◽  
Retinopathy Of Prematurity ◽  
Case Series ◽  
Serum Levels ◽  
Control Group ◽  
Serum Concentrations ◽  
Term Infants ◽  
Inflammatory Protein ◽  
Case Series Study ◽  
Inducible Protein

Abstract Background: To determine the serum concentrations of cytokines in infants with retinopathy of prematurity (ROP), and to evaluate the changes of serum vascular endothelial growth factor (VEGF) concentration who received intravitreal Conbercept (IVC). Methods: Case series study. Forty infants with ROP treated with IVC 0.25 mg and ten full-term infants with congenital cataract were included. Blood samples were collected before and 1 week, and 4 weeks after IVC. Serum levels of 45 types of cytokines were measured by multiplex bead assay. Results: In the ROP group, significantly higher concentrations of VEGF-A, VEGF-D, macrophage inflammatory protein 1 beta (MIP-1β), interferon-inducible protein-10 (IP-10), regulated on activation, normal T Cell expressed and secreted (RANTES), eotaxin, TNF-α, IL-18, EGF, SCF, PIGF-1, and β-NGF were measured, while lower concentrations of monocyte chemotactic protein-1 (MCP-1) and hepatocyte growth factor (HGF) were observed; when compared with the control group. No significant differences were detected in serum concentrations of VEGF-A and VEGF-D in ROP patients between baseline and 1 week, and 4 weeks after IVC treatment.Conclusion: Besides angiogenic factors, several inflammatory cytokines were associated with ROP. IVC 0.25 mg in ROP patients did not induce circulatory VEGF suppression at 1 week after injection.

Sign in / Sign up

Export Citation Format

Share Document